Palvella Therapeutics
PVLA
46 hedge funds and large institutions have $7.33M invested in Palvella Therapeutics in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 5 closing their positions.
1,300% more call options, than puts
Call options by funds: $14K | Put options by funds: $1K
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
7% more funds holding
Funds holding: 43 → 46 (+3)
0.02% less ownership
Funds ownership: 0.51% → 0.49% (-0.02%)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
39% less capital invested
Capital invested by funds: $12M → $7.33M (-$4.7M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$157K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$150K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$24.2K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$23.6K |
| 5 |
CM
CM Management
Gulf Breeze,
Florida
|
+$23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$984K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$29.3K |
| 3 |
JP Morgan Chase
New York
|
-$25.3K |
| 4 |
Millennium Management
New York
|
-$13.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$8.52K |
PVLA Hedge Fund Activity: Q4 2023 in Review
46 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q4 2023, worth a combined $7.33M — down 39% from $12M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new PVLA positions and 5 closed out — a net gain of 3 holders — while 6 added to existing stakes and 9 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $157K. The largest seller was Aquilo Capital Management, exiting entirely with an estimated $984K sold.
- 46 institutional investors held Palvella Therapeutics (PVLA) as of Q4 2023, up from 43 in Q3 2023.
- Funds reported $7.33M of Palvella Therapeutics stock for Q4 2023, down 39% quarter-over-quarter.
- 8 funds opened new Palvella Therapeutics positions in Q4 2023 and 5 closed out, a net change of +3 holders.
- The largest Palvella Therapeutics buyer in Q4 2023 was Renaissance Technologies, an estimated $157K added.
- The largest Palvella Therapeutics seller in Q4 2023 was Aquilo Capital Management, an estimated $984K sold.
Based on aggregated 13F filings for Q4 2023.